Generic Drugs Manufacturing Pharma Companies Pharma Production 
Pharmaceutical Technology
AUGUST 12, 2022
In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.
Pharmaceutical Technology
MARCH 22, 2023
In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues.
Expert insights. Personalized for you.
290 
Let's personalize your content